Artelo Biosciences (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways including the endocannabinoid system, today announced the appointment of Andrew Yates, Ph.D, as senior vice president and chief scientific officer. Dr. Yates is an experienced senior pharmaceutical executive, having most recently served at AstraZeneca in significant roles across a number of functional areas including development and commercial strategy, medical affairs and business development. Notably, Dr. Yates has been extensively involved in the life-cycle management of key multi-billion-dollar products including CRESTOR(R), FORXIGA(R) and KEYTRUDA(R). “We are extremely pleased to announce the appointment of Andy as our chief scientific officer,” said Gregory Gorgas, Artelo’s president and chief executive officer. “As a valuable member of our scientific advisory board, he has made significant contributions to the growth of Artelo’s business including the clinical advancement of ART27.13 as a development candidate for cancer-related anorexia. Andy’s expertise in biopharmaceutical drug development combined with his entrepreneurial background is expected to be of significant value in supporting the clinical development of Artelo’s next-generation therapies in multiple areas, including anorexia, cancer, PTSD, pain, and inflammation.”
To view the full press release, visit https://ibn.fm/koVB7
About Artelo Biosciences Inc.
Artelo Biosciences is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting endogenous signaling pathways including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.ArteloBio.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php